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Abstract Cystic fibrosis is caused by mutations in the cystic 
fibrosis transmembrane conductance regulator (CFTR) gene. 
The most frequent mutation is the deletion of F508 in the first 
nucleotide binding fold (NBF1). It induces a perturbation in the 
folding of NBF1, which impedes posttranslational maturation of 
CFTR. Determination of the three-dimensional structure of 
NBF1 would help to understand this defect. We present a novel 
model for NBF1 built from the crystal structure of bovine 
mitochondrial F^ATPase protein. This model gives a reasonable 
interpretation of the effect of mutations on the maturation of the 
protein and, in agreement with the CD data, leads to 
reconsideration of the limits of NBF1 within CFTR. 
© 1997 Federation of European Biochemical Societies. 
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1. Introduction 
Cystic fibrosis (CF) is a frequent genetic disease caused by 
mutations in the CF gene. This gene encodes the cystic fibrosis 
transmembrane conductance regulator (CFTR), a 1480 amino 
acid transmembrane protein which functions as a Cl~ chan-
nel. CFTR belongs to the phylogenetically ancient ABC trans-
porters which constitute the largest family of paralogous pro-
teins in prokarya, archaea and eukarya [1]. It was predicted to 
present two membrane spanning domains, a regulatory R do-
main, and two nucleotide binding folds (NBF1 and NBF2) 
[2]. The most frequent CF causing mutation is a deletion in 
NBF1 (AF508). This deletion probably induces a perturbation 
in the folding of NBF1, and consequently impedes CFTR 
from posttranslational maturation [3]. Therefore, knowledge 
of the three-dimensional (3D) structure of NBF1 would help 
to understand the effect CF mutations. In the absence of a 
known defined structure, we propose a new model for NBF1, 
built from the recently available X-ray structure of bovine 
mitochondrial Fi-ATPase protein [4], the only protein of 
known structure in the ABC family. We will show that this 
novel model facilitates the description of mutant phenotype in 
molecular terms. 
2. Building of the model 
2.1. Choice of the reference structure 
The choice of a relevant reference structure expected to 
have the same global fold is a critical step in order to build 
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a reliable model for NBF1. NBF1 of CFTR belongs to the 
superfamily of P-loop (also called Walker A) containing pro-
teins which present cc/ß structures (or Rossman folds), con-
sisting of a central ß-sheet surrounded by helices on both 
sides. Based on the topology of the ß-sheets, this superfamily 
is divided into four structural families [5]: 'kinases' such as 
adenylate kinase (ADK) [6], 'G proteins' such as p21-Ras [7] 
or elongation factor Tu [8], 'nitrogenase iron protein-like', 
and 'recA protein-like' such as Fi-ATPase, according to the 
SCOP structural data bank [5]. The 3D structure of ADK was 
chosen to build models for the NBF1 of CFTR because at 
that time no 3D structure of a representative member of the 
ABC family was known [1,9]. However, ADK and NBF1 are 
two evolutionarily quite unrelated molecules, indicated by the 
low overall sequence similarity (approximately 12% sequence 
similarity in conserved regions). 
Recently the 3D structure of the Ii domain of the FQFi-
ATPase was resolved [4], which shares higher sequence sim-
ilarity with NBF1, as shown below. Therefore we chose F | -
ATPase as reference structure for model building of NBF1, in 
which both the a and ß subunits of Fi-ATPase (referred as 
NBFcc and NBFß in the following) were used, to exploit all 
the information for model building. 
2.2. Strategy for building the model 
2.2.1. Sequence alignment and determination of conserved 
regions. First, the backbones of NBFa and NBFß were 
superimposed and graphically analyzed to identify the con-
served regions where the main chains match, and the non-
conserved regions where the main chains diverge. The align-
ment of NBF1 with NBFa and NBFß was based on the 
optimal match between known secondary structure elements 
in NBFa and NBFß and predicted in NBF1 by the PHD 
method (Profile fed neural network systems from Heidelberg) 
[10] and consensus motifs in the ABC family (Walker A, 
Walker B and C motifs) [11]. Insertions and deletions were 
introduced into non-conserved loops. The final sequence 
alignment is given in Fig. 1. According to this alignment 
NBF1 has approximately 28% sequence similarity with 
NBFa and NBFß in conserved regions, which is significantly 
higher than its sequence similarity with ADK. 
2.2.2. Structural constraints. In the conserved regions, 
conserved atoms were defined by the match in both the back-
bone and the side chains in NBFa, NBFß and NBF1. Dis-
tances between all conserved atoms were calculated in NBFa 
and NBFß, only short range distances being retained as con-
straints [12]. 
All possible <j), \|/ and %i dihedral angles that could be de-
duced from the conserved atoms were calculated in NBFa 
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and NBFß, and introduced as dihedral constraints [12]. In 
case of diverging side chains in NBFa and NBFß, and for 
residues situated in non-conserved loops, a %i value corre-
sponding to the most probable rotamer was taken as initial 
value, with a tolerance of ± 30° [13]. A total of 10 800 distance 
and 355 dihedral constraints were used as geometrical re-
straints. 
2.2.3. Computation of the model. The above constraints 
were used as input for distance-geometry calculations to com-
pute structures using a standard procedure with the DIANA 
software [14,15]. Structures were refined to release all stress by 
simulated annealing using the X-PLOR software [16]. During 
this refinement step, improvement of the Ramachandran dia-
gram for residues of non-conserved loops was obtained by 
applying an attraction potential towards allowed regions of 
the Ramachandran diagram [12-17]. 
2.3. Description and implications of the model 
The model for the NBFl domain of human CFTR is shown 
in Fig. 2 (codons 453-650). It contains a central open twisted 
6 stranded ß-sheet (strands L453-G458, N505-S511, N538-
G542, D567-D572, R600-V603, D614-I618) that alternate 
with 6 a-helices (K464-E474, Y517-D529, Q552-Y563, L581-
V591, S605-K611, S631-L636), which constitutes a global 
Rossman fold. In Fig. 2, strands are labelled S1-S6 and heli-
ces H1-H6. The most C-terminal extended strand (K643-
D648) is associated to strand 6, antiparallel to the other 
strands, and is labelled S7 in Fig. 2. F508 is situated in strand 
2 of the central hydrophobic ß-sheet, as shown in Fig. 2. Its 
deletion should destabilize the central ß-sheet and impair fold-
ing presumably by a perturbation of the hydrophobic collapse 
stage. The previous models based on ADK placed F508 in 
peripheral regions, and therefore could not predict the delete-
rious impact of AF508 on protein folding. 
In the model, the LSGGQ motif (or 'C motif) conserved 
among ABC transporters is situated at the surface of the 
domain which is consistent with its role to trigger interactions 
with other domains [18] of CFTR. 
Moreover, the model leads to a reconsideration of the limits 
of NBFl within the CFTR sequence. The N-terminal residue 
was initially defined by F434 and the C-terminal residue by 
1586, which is the terminal codon of exon 12. The whole exon 
13 was thought to encode the regulatory R domain [19]. How-
ever, the size of a domain should be defined by the necessary 
secondary elements that guarantee folding integrity. Accord-
ing to the present model, NBFl should extend to residue 
F650, i.e. by more than 60 residues into the region previously 
attributed to the regulatory R domain. This shift of the do-
main boundary is supported by sequence alignment with ABC 
transporters of other topologies, ending by an NBF domain at 
the C-terminus [20]. For example, the NBF domain of the 
ComA protein (the putative Streptococcus pneumoniae compe-
tence factor transporter) was aligned using the same method 
as for NBFl, as shown in Fig. 1. The alignment of NBFl and 
NBF of ComA also ends close to residue F650. 
3. Confrontation of the model with experimental data 
3.1. Analysis of exon 13 CFTR mutants 
After translation, the wild-type CFTR protein (130 kDa) 
matures, through different glycosylation steps, from a core-
glycosylated protein (150 kDa) in the endoplasmic reticulum 
(ER) to a mature protein (190 kDa) in the trans-Golgi [21]. 
Only the mature form will reach the cell membrane to form a 
functional chloride channel [22]. Some missense mutations or 
deletions, located in the CFTR coding region, result in a 
protein that only matures to the core-glycosylated form [23-
25]. These mutations seem to interfere with the folding pattern 
of the CFTR protein, which results in their degradation at the 
level of the ER [26]. The maturation patterns of six mutant R 
domain proteins were determined (Fig. 3): CFTR-L610S, 
CFTR-G628R and CFTR-L633P matured to the core-glyco-
sylated form, while CFTR-D648V, CFTR-T665S and CFTR-
R766M matured to the complete glycosylated form. These 
results would indicate that the R domain might be divided 
into two domains. Amino acids located in the first domain 
(amino acids 610-633) play an important role in the folding of 
the polypeptide since, after mutagenesis of these amino acids, 
the resulting protein is recognized and retained by the control 
system that operates in the ER, while missense mutations 
located in the second domain (648-766) seem to have no effect 
on maturation. Preliminary results on a total of 16 different 
missense mutations in the R domain confirm this differential 
effect of mutations in the two R domain sequences [27]. These 
results are consistent with the assumption that the first part of 
the R domain is in fact the C-terminal part of NBFl. 
3.2. CD spectroscopy 
Since ADK has been used previously to build a model for 
the NBF of ABC transporters [1], the validity of this ap-
proach may be tested by evaluation of the secondary structure 
profiles of NBFl and ADK by CD spectroscopy. 
The heterologously expressed NBFl construct encompasses 
the complete sequence from the initially defined boundaries of 
the transmembrane to the regulatory domains [28]. As shown 
in Table 1, bundles of a-helices were found to be the major 
components in both NBFl and ADK at pH 6-7 and low ionic 
strength. However, the susceptibility of secondary structure to 
pH and ATP was different in the two proteins. Loss of a-helix 
and increase of random coil was observed for NBFl when pH 
was shifted from pH 7 to pH 8, whereas a similar change in 
ADK required the more alkaline pH 9 (Table 1). The most 
striking difference between NBFl of CFTR and ADK was 
seen when the concentration of ATP was varied at pH 8 
between 0 and 4 mM (Table 1). Secondary structure of 
ADK was insensitive to ATP. In the case of NBFl, however, 
the addition of low concentrations of ATP induced a gain of 
ß-sheet structure and compensatory loss of random coil. 
When the concentration of ATP was further increased to 
4 mM, a-helical contents of NBFl dropped below 10% (Table 
1). These data suggest that NBFl structure is strongly influ-
Fig. 1. Sequence alignment of NBFa and NBFß of Fi-ATPase, NBFl of CFTR, and NBF of ComA. Positions of a-helices (known in NBFa 
and NBFß and predicted in NBFl and NBF of ComA) are indicated by striped bars, while ß-sheets (also known in NBFa and NBFß and pre-
dicted in NBFl and NBF of ComA) are indicated by gray bars. Conserved regions are boxed. 
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of NBFl with NBFa/ß of F^ATPase appears to provide a 
better fit between the structural and functional studies. This 
model also gives a more reasonable interpretation of the effect 
of mutations on the maturation of the proteins. Indeed, the 
majority of the mutations in the NBFl, including those in the 
first part of the domain previously considered to be the R 
domain, appear to result in premature degradation of the 
CFTR protein. Moreover, the comparison of the CD data 
of NBFl and ADK shows that there is a contradiction be-
tween the initial definition of NBFl and a kinase global fold. 
Further modeling of the other domains of the CFTR pro-
tein will probably result in the reinterpretation of the effect of 
many other mutations and thereby lead to a reconsideration 
of the phenotypic effects of the different mutations. 
5. Materials and methods 
Fig. 2. Model for the NBFl domain. Residues belonging to the 
NBFl domain as initially defined (up to residue 1586) are repre-
sented in gray. Residues belonging to the R domain as initially de-
fined (starting at residue F587) are represented in black. Helices and 
sheets are labelled H1-H6 and S1-S7 respectively. The F508 residue 
side chain is shown by a ball-and-stick representation. The LSGGQ 
sequence is labelled and is exposed at the surface of the domain. 
This figure was drawn using the program MOLSCRIPT [32]. 
enced by ATP and that at least three different conformations 
exist at zero, low and high ATP concentrations, which is not 
expected for a globular folded protein. This differential re-
sponse of NBFl and ADK to pH and ATP suggests that 
either NBFl (in its initial boundaries) represents a truncated 
domain or/and NBFl and ADK do not share the same sec-
ondary structure characteristics. 
4. Conclusion 
The structural and functional studies of NBFl of the CFTR 
protein presented here suggest that the structural model ini-
tially proposed for this domain might not be adequate. In 
contrast, our novel structural model based on the homology 
5.1. Cloning and purification of GST-NBF1 and GST 
The NBFl CFTR cDNA fragment (codons 347-596) gen-
erated by primer-directed reverse transcription of RNA from 
T84 cells and subsequent PCR was cloned in-frame into the 
Smal site of glutathione 5-transferase (GST) encoding expres-
sion vector pGEX-3X (Pharmacia) and introduced into Es-
cherichia coli DH5a cells. Recombinant E. coli bacteria were 
grown at 37°C under vigorous shaking in 20 ml Luria broth 
supplemented with 0.75 iig/ml ampicillin until the late expo-
nential phase. After dilution with 100 ml medium, fermenta-
tion was continued for 1 h and then the expression of the 
fusion protein was induced by IPTG (0.25 mM final concen-
tration) for a further 3^1 h period. Cells were harvested by 
centrifugation (2500 Xg; 4°C; 10 min), resuspended in ice-
cold 0.1 M phosphate/10% (v/v) glycerol buffer, pH 8, and 
lysed by sonication (six 5 s pulses at 0°C). The suspension 
was centrifuged (12000Xg-; 4°C; 10 min) and the pellet was 
solubilized in 2 ml denaturation buffer (8 M urea, 2% (v/v) 
SDS, 20 mM EDTA, 0.06M Tris/HCl, pH 6.8, 10% (v/v) 
glycerol, 0.05 M DDT). Proteins were separated by prepara-
tive single-slot SDS-12% PAGE (13.5 X18 X 0.2 cm gel, 2.2 VI 
cm, 16 h, 20°C) and visualized by negative staining with 
CuCl2 [29]. Fusion protein was gel electroluted (5 V/cm, 3^1 
h, 4°C) into 2 ml electrophoresis buffer supplemented with 
5 mM EDTA for the complexation of copper ions. Ionic 
Table 1 
Secondary structure elements of CFTR NBFl and adenylate kinase determined by CD 
Secondary structure 
(%) 
A: Variation of pH 
pH 5 
p H 6 
p H 7 
pH 8 
p H 9 
elements 
value 
NBFl CFTR 
a-helix (±5%) ß-sheet (±8%) 
nd 
50 
45 
26 
31 
B : Variation of ATP concentration at pH 8 
0 mM ATP 
0.25 mM ATP 
0.5 mM ATP 
1 mM ATP 
2 mM ATP 
4 mM ATPa 
26 
23 
30 
26 
30 
8 
nd 
17 
17 
24 
18 
24 
39 
37 
38 
32 
30 
random coil ( ± 8%) 
nd 
33 
38 
50 
51 
50 
38 
34 
37 
38 
62 
Adenylate 
a-helix (± 
45 
49 
52 
51 
27 
51 
49 
57 
52 
48 
57 
kinase 
5%) ß-sheet (±8%) 
24 
24 
23 
21 
14 
21 
22 
15 
23 
19 
10 
random coil ( ± 8%) 
30 
27 
28 
28 
59 
28 
29 
29 
26 
33 
38 
nd, not determined. 
a, absolute error ±(10-20%) because of high absorbance. 
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Fig. 3. Representative example of a pulse chase and immunoprecipi-
tation of CFTR from transfectants. COS cells transfected with wild-
type CFTR-L610S and CFTR-R766M were metabolically labelled, 
chased and CFTR was immunoprecipitated and separated on a 
SDS-PAGE gel. The different maturation forms are indicated: A 
(= translation product), B (= core-glycosylated protein) and C (= ma-
ture CFTR protein). 
strength of the protein solution was gradually reduced in 12-
18 h intervals by dialysis at 4°C in phosphate buffer supple-
mented with 1 mM MgCVATP to facilitate refolding and 
with Dowex resin to absorb SDS (buffer 1: 0.1 M phosphate, 
10% (v/v) glycerol; buffer 2: 0.05 M phosphate, 5% (v/v) 
glycerol; buffer 3: 0.02 M phosphate, 5% (v/v) glycerol; buffer 
4: 0.02 M phosphate). The protein solution was stored in 0.02 
M phosphate, pH 8 at -70°C until use. 
According to spectrophotometric assay of SDS-/>-rosaniline 
complexes [30] the purified proteins always contained less than 
0.001% SDS. Fusion proteins were cleaved with factor Xa 
(Boehringer) at a molar ratio of 10:1 to 200:1 in 50 mM 
Tris-HCl/150 mM NaCl/1 mM CaCl2, pH 7.5 (25°C, 2-3 h) 
and then separated by SDS-PAGE. Porcine ADK was pur-
chased from Boehringer Mannheim. 
5.2. CD spectroscopy 
Circular dichroism spectra of proteins (concentration range 
0.5-1.5 mg/ml) were recorded in 20 mM phosphate buffer at 
ambient room temperature in 0.01 cm cuvettes (volume 58 ul) 
in a Jobin-Yvon Dichrograph R J . Mark III. The band width 
was always 0.5 nm and the speed 0.5 nm/s (time constant 2 s). 
After registering the baseline, four consecutive scans ranging 
from 245 nm down to 184 nm were accumulated. Cumulative 
spectra were stored in a digital recorder, processed and ana-
lyzed numerically in the range 190-243 nm (0.5 nm incre-
ments) in terms of a-helices, ß-pleated sheets and residual 
structure content with myoglobin, lysozyme, lactate dehydro-
genase, papain and ribonuclease A as reference proteins [31]. 
The quality of the data analysis could be controlled visually 
by displaying the superposition of the experimental and the-
oretical spectra. Since the CD spectra of GST-NBF1 CFTR 
were identical prior to and after cleavage with factor Xa, the 
CD spectral increments of GST and NBF1 were assumed to 
be additive and hence the secondary structure elements of 
NBF1 were calculated from the spectra of GST and fusion 
protein. 
5.3. Expression of wild-type and mutant CFTR proteins 
The CFTR.WT coding sequence was excised from the 
pTG5960 plasmid (Transgene, Strasbourg, France) and 
cloned into the eukaryotic expression vector pcDNA3 (Invi-
trogen BV, Leek, The Netherlands). The mutations L610S (tc 
at 1961), G628R (gc at 2014), L633P (tc at 2030), D648V (at 
at 2075), T665S (at at 2125) and R766M (gt at 2429) (nucleo-
tide and amino acid assignment according to [2]) were intro-
duced using the Transformer Site-Directed Mutagenesis kit 
(Clontech, Heidelberg, Germany). COS cells were electropo-
rated with 20 ug plasmid DNA (BioRad Gene Pulser, BioRad 
Laboratories, Hercules, CA, USA). After 48-72 h cells were 
labelled during a 30 min pulse with 400 |j.Ci Translabel (ICN 
Pharmaceuticals, Costa Mesa, CA, USA) and chased in DME 
F12 (Life Technologies, Merelbeke, Belgium) +10% FCS (Hy-
clone Laboratories Inc., Logan, UT, USA). The cells were 
then lysed in ice-cold DIPPA buffer (20 mM Tris, 150 mM 
NaCl, 1% Na-deoxycholate, 1% Triton X-100, 0.1% SDS, pH 
7.4) containing protease inhibitors. After immunoprecipita-
tion with an anti-CFTR monoclonal antibody directed against 
the C-terminal part of CFTR (Genzyme Diagnostics, Cam-
bridge, MA, CA), the immune complexes were purified on 
protein A beads (Pharmacia Biotech, Uppsala, Sweden) and 
loaded on a 4-12% SDS gel (Novex, San Diego, CA, USA). 
After drying of the gel, the signals were visualized by means of 
autoradiography. 
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